Earnings Results
Gain Therapeutics (NASDAQ:GANX) reported quarterly earnings results on August 11, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.11, beating the consensus estimate of $-0.15 by $0.04 per share. Revenue came in at , meeting the estimate of .
Company Overview
Gain Therapeutics's stock moved following the earnings release. The stock currently trades at $1.83 with a market capitalization of $148.5M.
Gain Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 27% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Gain Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Gain Therapeutics Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q2 (Aug 2026) | $-0.11 | $-0.15 | +26.7% |
| Q1 (May 2026) | $-0.13 | $-0.14 | +7.1% |
| Q4 (Mar 2026) | $-0.11 | $-0.14 | +21.4% |
| Q3 (Sep 2025) | $-0.15 | $-0.15 | +2.0% |
Related Tools: Earnings Calendar | View GANX Stock Page
Frequently Asked Questions
When does Gain Therapeutics report earnings?
Check the latest earnings dates on our GANX earnings page or the Earnings Calendar.
Did GANX beat earnings estimates?
See the full Q2 results including EPS actual vs estimate on our GANX earnings page.